IsoPlexis is a life sciences company building solutions to accelerate the development of curative medicines and personalized therapeutics. Co.'s single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. Co.'s initial focus has been on developing applications of its platform for cancer immunology and cell and gene therapy. Co.'s platform is an end-to-end solution comprised of its proprietary IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. The ISO average annual return since 2021 is shown above.
The Average Annual Return on the ISO average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ISO average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ISO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|